Form 4: Cyclo Therapeutics Director Shawn Cross Receives Stock Grant and Options

Director Shawn Cross received 8,887 shares of common stock and options to purchase 15,562 shares of Cyclo Therapeutics, Inc. (CYTH) on June 3, 2024.

Summary

• On June 3, 2024, Shawn Cross, a director of Cyclo Therapeutics, Inc., received 8,887 shares of common stock.
• These shares were granted in lieu of cash compensation for the first quarter of 2024, based on a price of $1.28 per share.
• Cross also received options to purchase 15,562 shares of common stock at an exercise price of $1.28.
• The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
• Following these transactions, Cross directly owns 81,493 shares of common stock and options for 15,562 shares.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting the grant of stock and options to a director. The fact that the director is taking stock in lieu of cash is a mildly positive signal.

Positives

• The director's acceptance of stock in lieu of cash may signal confidence in the company's future performance.
• The vesting schedule of the options incentivizes the director to remain engaged with the company over the next year.

Future Outlook

The document does not contain specific forward-looking statements, but the option vesting schedule suggests a continued relationship between the director and the company.

Industry Context

Stock grants and options are common forms of compensation for directors, aligning their interests with those of shareholders. The specific terms of the grant and vesting schedule are typical for director compensation packages.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• The vesting schedule of one year for the options is fairly standard.
• The exercise price of $1.28 is at the money as of the grant date.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock as a positive sign of alignment with their interests.
• The dilution effect of the stock grant is minimal given the relatively small number of shares involved.

Key Dates